NHS England has announced it has secured a definitive cystic fibrosis drugs agreement with Vertex Pharmaceuticals, to use all three of their UK-licensed medicines.
Steve Jones, Chair Action for Pulmonary Fibrosis and Board Member EU-IPFF and Gisli Jenkins from Nottingham University Hospitals, explain idiopathic pulmonary fibrosis (IPF), an incurable lung disease.
Karen Moor and Marlies Wijsenbeek from the Erasmus Medical Center, Rotterdam explore the role of eHealth tools in idiopathic pulmonary fibrosis care and research.
Michael Roth, Research Group Leader at University Hospital Basel asks if disturbed cell-cell interaction causes asthma and provides a fascinating response.
The restriction or inhalation of common sugar could one day treat a range of respiratory diseases, according to new research led by University of Manchester biologists.
The University of Manchester found that patients with common lung diseases are substantially more likely to suffer a heart attack and develop other major heart problems.
New figures show nearly 18 million patients are exposed to pollution, registered at GP surgeries with unsafe levels in the UK: read on to find out who is affected by these findings
Michael Roth, Research Group Leader at the University Hospital Basel explains what asthma is, its health impact and charts research landscape in the field.
Michael Roth, Research Group Leader at the University Hospital Basel & University Basel share his expertise on asthma and COPD, the most prevalent chronic inflammatory diseases of the lung globally
An innovative new surgery could provide a breakthrough in treating early-stage lung cancer, based on a review of some of the first patients to receive the treatment.
Michael Roth, Research Group Leader at University Hospital Basel argues for the clear need to improve the diagnosis of chronic inflammatory lung diseases
Michael Roth, Research group leader at the University & University Hospital Basel explores the current state of chronic inflammatory lung diseases, from the molecular biology perspective
Associate Professor of Medicine, Anesthesiology and Critical Care at Université Clermont Auvergne, Matthieu Jabaudon assesses the RAGE pathway in at-risk critically ill patients and asks if this is a step towards better acute respiratory distress syndrome (ARDS) prediction
Cecilia Van Cauwenberghe, from TechVision Group, Frost & Sullivan provides a fascinating overview of acute respiratory distress syndrome, including refocusing clinical concerns and disease management, as well as the overall characteristics and health implications
Revolutionary discovery brings hope to lung disease sufferers after scientists from Université Paris-Saclay find a way to stop the deterioration of the arteries
